Director of Accounting

Opportunity The Director of Accounting is responsible for monthly general ledger close process, account analyses, financial reporting, analytical reviews, technical accounting research, treasury, among other activities. This role drives financial integrity by architecting robust internal controls, optimizing the end-to-end close process, and spearheading financial system enhancements. The ideal candidate is a collaborative, forward-thinking leader who leverages deep technical accounting expertise to deliver actionable financial insights, foster cross-functional partnerships, and align financial operations with overarching corporate strategy. Overview Director of Accounting Reports to Associate VP of Finance Responsibilities Financial Operations & Reporting Direct the preparation of comprehensive financial statements, ensuring strict adherence to month-end close schedules and executive-level accuracy for all adjustments and accruals. Govern the comprehensive management of general ledgers, accounts payable, revenue distribution, fixed assets, operating expenses, and insurance records. Manage cash flows working with Corporate HQ on cash needs and managing of cash balance via operations. Perform analytical review of financial results and understand factors driving variances. Strategic Leadership & Partnership Cultivate strong, strategic partnerships across all business units, acting as a trusted advisor to cross-functional leaders to drive profitability and operational growth. Partner strategically with Corporate IT to champion and deploy financial system enhancements, driving automation and embedding best practices into enterprise architecture. Collaborate with tax leadership to ensure optimal tax strategy execution, providing critical financial insights and data for high-level tax initiatives. Spearhead high-impact strategic initiatives—including enterprise software implementations and advanced management reporting—to support decision-making and continuous business improvement. Compliance, Audit & Risk Management Architect and enforce best-in-class policies, procedures, and internal controls across accounting operations and financial management to mitigate risk and scale operations. Direct all interim and year-end audit engagements and compliance reviews, serving as the primary strategic liaison for external auditors. Lead complex technical accounting research, assessing the impact of new regulatory pronouncements and advising the executive team on strategic accounting implications. Qualifications Bachelor’s degree in Accounting MBA or CPA license is strongly preferred. Experience in public accounting and/or pharmaceuticals industry is preferred Experience in Gross to Net and Inventory accounting is strongly preferred Minimum of 8-10 years of recent financial reporting or relevant audit experience, with at least 15 years of experience in Financial Accounting Strong attention to detail is required. Proficiency in Microsoft Office and SAP S4 HANA is preferred Advanced knowledge of general accounting (US GAAP) Excellent analytical, problem solving and decision-making skills Effective verbal, listening and written communication skills Effective organizational, stress and time management skills Ability to provide leadership and manage personnel Demonstrates a sense of urgency and ability to meet deadlines Ability to work independently or as a team member Ability to handle multiple tasks High level of personal and professional integrity. Salary & Benefits Base Salary Range of $225,000-$235,000. Menarini Stemline offers generous compensation and benefits packages, including Short- and Long-Term Incentive Programs, Fidelity 401(k) (with company match), Anthem Premier PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs. Equal Opportunity Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran. Reasonable Accommodations Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions. Company Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history. The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market. Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents. Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF). Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines. Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023. It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business. #J-18808-Ljbffr